{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:47:50Z","timestamp":1788814070218,"version":"build-2803163510"},"reference-count":82,"publisher":"Informa UK Limited","issue":"4","funder":[{"name":"National Cancer Institute\/National Institutes of Health"},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2026,3,4]]},"DOI":"10.1080\/14656566.2026.2651280","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T14:21:59Z","timestamp":1774362119000},"page":"311-318","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Tyrosine kinase inhibitors, chronic myeloid leukemia, and pregnancy: pharmacotherapeutic challenges and recommendations"],"prefix":"10.1080","volume":"27","author":[{"given":"Fadi G.","family":"Haddad","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen T.","family":"Chifotides","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereen","family":"Sakkal","sequence":"additional","affiliation":[{"name":"University of Montreal","place":["Quebec, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27443"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0220"},{"key":"e_1_3_4_5_1","volume-title":"Key statistics for chronic myeloid leukemia","author":"American Cancer Society","year":"2026","unstructured":"American Cancer Society. Key statistics for chronic myeloid leukemia. 2026 Mar 3. https:\/\/www.cancer.org\/cancer\/types\/chronic-myeloid-leukemia\/about\/statistics.html"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21731"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61510-4"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.73"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-283580"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720966120"},{"key":"e_1_3_4_11_1","first-page":"834","volume-title":"Harrison\u2019s principles of internal medicine","author":"Kantarjian H","year":"2025","unstructured":"Kantarjian H, Jabbour E. Chronic myeloid leukemia. In: Longo D, Fauci A Kasper D, editors. Harrison\u2019s principles of internal medicine. New York (NY): McGraw-Hill Education; 2025. p. 834\u2013843."},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35611"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.07.017"},{"issue":"1","key":"e_1_3_4_14_1","first-page":"1","article-title":"Management of chronic myelogenous leukemia in pregnancy","volume":"35","author":"Bhandari A","year":"2015","unstructured":"Bhandari A, Rolen K, Shah BK. Management of chronic myelogenous leukemia in pregnancy. Anticancer Res. 2015;35(1):1\u201311.","journal-title":"Anticancer Res"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2317-z"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-015-0519-0"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-023-00689-5"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2023.2201429"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19491"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-024-01743-9"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01603-z"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30192-X"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26550"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.09.012"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10935"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.6.1232"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1986.tb08635.x"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199809)59:1<101::AID-AJH23>3.0.CO;2-D"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20476"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgo.2003.11.014"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.9876"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1515\/JPM.2000.047"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830460312"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02183-0"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-020-02147-1"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11223"},{"issue":"7","key":"e_1_3_4_37_1","first-page":"1448","article-title":"The effects of hydroxyurea and related compounds on the rat fetus","volume":"26","author":"Chaube S","year":"1966","unstructured":"Chaube S, Murphy ML. The effects of hydroxyurea and related compounds on the rat fetus. Cancer Res. 1966;26(7):1448\u20131457.","journal-title":"Cancer Res"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609074361"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402168"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26495"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0027-9684(15)31072-5"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1849672"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02664-w"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-378919"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0047"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2015.05.009"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi398"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-014-1084-5"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.10.002"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107367"},{"key":"e_1_3_4_51_1","volume-title":"Embryology, weeks 6\u20138","author":"Donovan MF","year":"2025","unstructured":"Donovan MF, Cascella M. Embryology, weeks 6\u20138. Treasure Island (FL): StatPearls; 2025."},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1347929"},{"issue":"1","key":"e_1_3_4_53_1","first-page":"1","article-title":"Update on overall prevalence of major birth defects\u2013Atlanta, Georgia, 1978\u20132005","volume":"57","author":"Centers for Disease C, Prevention","year":"2008","unstructured":"Centers for Disease C, Prevention. Update on overall prevalence of major birth defects\u2013Atlanta, Georgia, 1978\u20132005. MMWR Morb Mortal Wkly Rep. 2008;57(1):1\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.l869"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.n.064"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-114900"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2014.028"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-2-42"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.5430\/jhm.v2n3p74"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.18.00211"},{"issue":"8","key":"e_1_3_4_61_1","first-page":"997","article-title":"Guidelines for the management of nilotinib (Tasigna)-induced side effects in chronic myelogenous leukemia: recommendations of French intergroup of cml (Fi-LMC group)","volume":"97","author":"Etienne G","year":"2010","unstructured":"Etienne G, Milpied B, Rea D, et al. Guidelines for the management of nilotinib (Tasigna)-induced side effects in chronic myelogenous leukemia: recommendations of French intergroup of cml (Fi-LMC group). Bull Cancer. 2010;97(8):997\u20131009.","journal-title":"Bull Cancer"},{"issue":"1","key":"e_1_3_4_62_1","first-page":"22","article-title":"Loss of pregnancy in a patient with chronic myeloid leukemia during treatment with nilotinib","volume":"6","author":"Arnall J","year":"2016","unstructured":"Arnall J, Muluneh B. Loss of pregnancy in a patient with chronic myeloid leukemia during treatment with nilotinib. J Hematol Oncol Pharm. 2016;6(1):22\u201327.","journal-title":"J Hematol Oncol Pharm"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124430"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05280-9"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e328352a8fe"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3730"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.022764"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24186"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clp.2019.10.001"},{"key":"e_1_3_4_70_1","unstructured":"US FDA. Bosulif (bosutinib) prescribing information. 2017 [cited 2026 Feb 17]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/203341s009lbl.pdf"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.2217\/ijh-2020-0004"},{"key":"e_1_3_4_72_1","unstructured":"Ponatinib\u2019s investigator brochure. 2013 [cited 2026 Feb 17]. Available from: www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/203469Orig1s007 s008.pdf"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(21)01245-3"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200186"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2013.03.001"},{"key":"e_1_3_4_76_1","unstructured":"Asciminib\u2019s investigator brochure. 2021 [cited 2026 Feb 17]. Available from: www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/215358Orig1s000 Orig2s000MultidisciplineR.pdf"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-5566"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06238-9"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-051391"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2018.027"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.11.011"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0826"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-016-4262-z"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2343758"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2651280","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T08:03:02Z","timestamp":1777017782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2026.2651280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":82,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3,4]]}},"alternative-id":["10.1080\/14656566.2026.2651280"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2026.2651280","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-12-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}